Nagi; Arwinder

Patent Applications and Registrations

Patent applications and USPTO patent grants for Nagi; Arwinder.The latest application filed is for "micronized tanaproget, compositions, and methods of preparing the same".

Company Profile

0.7.15

Nagi; Arwinder - Moorpark CA
Nagi; Arwinder - Thiells NY US

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Micronized Tanaproget, Compositions, And Methods Of Preparing The Same App 20140328925 - Nagi; Arwinder ; et al.	2014-11-06
Tanaproget Compositions Containing Ethinyl Estradiol App 20140194398 - Nagi; Arwinder ; et al.	2014-07-10
Tanaproget compositions containing ethinyl estradiol Grant 8,664,208 - Nagi , et al. March 4, 2	2014-03-04
Micronized Tanaproget and Compositions Containing Same App 20130337058 - Nagi; Arwinder ; et al.	2013-12-19
Tanaproget Compositions Containing Ethinyl Estradiol App 20120114748 - Nagi; Arwinder ; et al.	2012-05-10
Pantoprazole multiparticulate formulations Grant 7,838,027 - Venkata Ramana Rao , et al. November 23, 2	2010-11-23
Purified form of tanaproget Grant 7,786,297 - Chatlapalli , et al. August 31, 2	2010-08-31
Pharmaceutical Formulations Of An Anhydrate Crystal Form Of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol App 20090239920 - KRISHNAN; Mahesh K. ; et al.	2009-09-24
Pantoprazole multiparticulate formulations Grant 7,553,498 - Venkata Ramana Rao , et al. June 30, 2	2009-06-30
Pantoprazole multiparticulate formulations Grant 7,550,153 - Venkata Ramana Rao , et al. June 23, 2	2009-06-23
Pantoprazole multiparticulate formulations Grant 7,544,370 - Venkata Ramana Rao , et al. June 9, 2	2009-06-09
Pharmaceutical Formulations Of An Anhydrate Crystal Form Of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol App 20080241234 - KRISHNAN; Mahesh K. ; et al.	2008-10-02
Sustained-release Tablet Formulations Of Piperazine-piperidine Antagonists And Agonists Of The 5-ht1a Receptor Having Enhanced Intestinal Dissolution App 20080226714 - Wen; Hong ; et al.	2008-09-18
Pharmaceutical Formulations Of A Crystal Form Of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol App 20080175901 - Krishnan; Mahesh K. ; et al.	2008-07-24
Pharmaceutical Formulations Of An Anhydrate Crystal Form Of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol App 20080175900 - KRISHNAN; Mahesh K. ; et al.	2008-07-24
Pantoprazole multiparticulate formulations App 20070196444 - Ramana Rao; Sripriya Venkata ; et al.	2007-08-23
Pantoprazole multiparticulate formulations App 20070196443 - Ramana Rao; Sripriya Venkata ; et al.	2007-08-23
Pantoprazole multiparticulate formulations App 20070042033 - Venkata Ramana Rao; Sripriya ; et al.	2007-02-22
Tanaproget compositions containing ethinyl estradiol App 20060280800 - Nagi; Arwinder ; et al.	2006-12-14
Purified form of tanaproget App 20060247236 - Chatlapalli; Ramarao ; et al.	2006-11-02
Pantoprazole multiparticulate formulations App 20050129761 - Venkata Ramana Rao, Sripriya ; et al.	2005-06-16

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.